Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

This study is being done to answer the following questions: Can adding the medicine capivasertib to standard treatment options help keep the cancer from growing or spreading? Standard treatment is the care that most people receive for metastatic breast cancer. This study looks at different treatment combinations for people with metastatic breast cancer that's HR-positive and HER2-negative. Researchers hope to learn: How well the cancer responds to different treatment combinations? How long patients live after receiving different treatment combinations? How cancer-related markers in the blood (called circulating tumor DNA or ctDNA) change with treatment - and whether those changes are linked to certain results? What happens when patients switch treatments after the cancer gets worse?